List of Microbiome Companies in Maryland - 9

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

"EzBiome, Inc. is a microbiome company promising the discovery of exciting new biology and transformative therapeutics through data- and database-driven microbial taxonomy, new bacterial species concept and standard, and the use of carefully curated and expert validated reference database that includes >3,000 new species. We cater world-class sample to discovery services on microbial identification, microbial genomics, microbiome bioinformatics, and database expertise for businesses worldwide for regulated and non-regulated applications to shorten the time for microbiota-based discovery and development of therapeutics and companion diagnostics for microbiome-related diseases."

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. The company makes phage that target E. coli, Salmonella, and Listeria in pet and human food.Intralytix has developed and is continuing to develop phage preparations for preventing and treating bacterial diseases of pets and other animals, including agriculturally-important animals. Other products include phage mixtures as probiotics.Intralytix’s is also developing phage preparations for treating infected wounds.

Our mission is to combat dysbiosis* in the human body. To that end, we aim to commercialize antimicrobial peptide therapies to safely restore balance to the gut's microbial flora and overcoming disease. P4 Microbiome was founded by Johns Hopkins University professors Phillip Phan and Jay Pasricha. The company took over the clinical development of P4M01 from the US Army in February of 2020. Together they recognized the immense potential of this discovery, not only for oral health, but also for solving dysbiosis in the GI tract. Beginning with our gingivitis indication, we will work our way down the gastrointestinal (GI) tract, addressing conditions including small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) by correcting the underlying dysbiosis that drives pathology. *Dysbiosis: A change in the microbial composition, especially in the GI tract, that causes imbalance between beneficial and potentially pathogenic bacteria.

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.